Lonza Group AG Share Price Deutsche Boerse AG

Equities

LO3A

US54338V1017

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG 07:07:52 14/06/2024 BST 5-day change 1st Jan Change
50.5 EUR -0.98% Intraday chart for Lonza Group AG -1.94% +35.75%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 6.66B 7.48B 6.98B 590B Sales 2025 * 7.62B 8.56B 7.99B 675B Capitalization 34.64B 38.9B 36.32B 3,069B
Net income 2024 * 893M 1B 936M 79.12B Net income 2025 * 1.11B 1.24B 1.16B 98.08B EV / Sales 2024 * 5.61 x
Net Debt 2024 * 2.72B 3.05B 2.85B 241B Net Debt 2025 * 3.32B 3.73B 3.48B 294B EV / Sales 2025 * 4.98 x
P/E ratio 2024 *
38.8 x
P/E ratio 2025 *
31 x
Employees 18,000
Yield 2024 *
0.95%
Yield 2025 *
1.11%
Free-Float 96.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.98%
1 week-1.94%
Current month+2.64%
1 month-1.94%
3 months+3.91%
6 months+48.53%
Current year+35.75%
More quotes
1 week
50.50
Extreme 50.5
52.00
1 month
48.60
Extreme 48.6
54.00
Current year
36.40
Extreme 36.4
56.50
1 year
32.00
Extreme 32
57.50
3 years
32.00
Extreme 32
61.00
5 years
32.00
Extreme 32
61.00
10 years
32.00
Extreme 32
61.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 24/04/17
Director of Finance/CFO 52 30/11/21
Chief Operating Officer 55 31/07/22
Members of the board TitleAgeSince
Director/Board Member 63 15/04/14
Director/Board Member 66 15/04/14
Director/Board Member 58 04/05/22
More insiders
Date Price Change Volume
14/06/24 50.5 -0.98% 0
13/06/24 51 +0.99% 0
12/06/24 50.5 -1.94% 400
11/06/24 51.5 -0.96% 0
10/06/24 52 +0.97% 103

Delayed Quote Deutsche Boerse AG, June 14, 2024 at 07:07 am

More quotes
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
480.3 CHF
Average target price
583.7 CHF
Spread / Average Target
+21.53%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW